Triumvira Immunologics, Inc.
9433 Bee Cave Rd
11 articles with Triumvira Immunologics, Inc.
Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022
Triumvira Immunologics announced it will present two posters at the American Association for Cancer Research Annual Meeting, taking place April 8-13, 2022 in New Orleans.
3/23/2022Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms.
Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million
Triumvira Immunologics today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million.
Triumvira Immunologics today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians.
Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting
Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients with solid tumors, announced the presentation of preclinical data from its proof-of-concept study in gastric cancer.
Triumvira Immunologics today announced that it has appointed Deyaa Adib, M.D., to serve as the company’s Chief Medical Officer, effective immediately.
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
Triumvira's T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza's Cocoon ® platform at the C3i Center Inc (C3i) in Montreal
Triumvira Immunologics (“Triumvira”) today announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors.
Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions
Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin to Senior Vice President of Finance.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.